217 related articles for article (PubMed ID: 30423192)
21. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
22. The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.
Elmer JJ; Christensen MD; Barua S; Lehrman J; Haynes KA; Rege K
Biotechnol Bioeng; 2016 Jun; 113(6):1345-1356. PubMed ID: 26614912
[TBL] [Abstract][Full Text] [Related]
23. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
25. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Cycon KA; Mulvaney K; Rimsza LM; Persky D; Murphy SP
Immunology; 2013 Oct; 140(2):259-72. PubMed ID: 23789844
[TBL] [Abstract][Full Text] [Related]
27. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Wilson AJ; Gupta VG; Liu Q; Yull F; Crispens MA; Khabele D
Neoplasia; 2022 Feb; 24(2):63-75. PubMed ID: 34933276
[TBL] [Abstract][Full Text] [Related]
28. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibition promotes intratumoral CD8
McCaw TR; Li M; Starenki D; Liu M; Cooper SJ; Arend RC; Forero A; Buchsbaum DJ; Randall TD
Cancer Immunol Immunother; 2019 Dec; 68(12):2081-2094. PubMed ID: 31720815
[TBL] [Abstract][Full Text] [Related]
30. MHC class II expression through a hitherto unknown pathway supports T helper cell-dependent immune responses: implications for MHC class II deficiency.
Buch T; Polic B; Clausen BE; Weiss S; Akilli-Ozturk O; Chang CH; Flavell R; Schulz A; Jonjic S; Waisman A; Förster I
Blood; 2006 Feb; 107(4):1434-44. PubMed ID: 16254146
[TBL] [Abstract][Full Text] [Related]
31. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
[TBL] [Abstract][Full Text] [Related]
32. Targeting SALL4 by entinostat in lung cancer.
Yong KJ; Li A; Ou WB; Hong CK; Zhao W; Wang F; Tatetsu H; Yan B; Qi L; Fletcher JA; Yang H; Soo R; Tenen DG; Chai L
Oncotarget; 2016 Nov; 7(46):75425-75440. PubMed ID: 27705911
[TBL] [Abstract][Full Text] [Related]
33. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
34. Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.
Kalin JH; Eroglu A; Liu H; Holtzclaw WD; Leigh I; Proby CM; Fahey JW; Cole PA; Dinkova-Kostova AT
PLoS One; 2019; 14(3):e0213095. PubMed ID: 30865688
[TBL] [Abstract][Full Text] [Related]
35. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
36. The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.
McCaw TR; Li M; Starenki D; Cooper SJ; Liu M; Meza-Perez S; Arend RC; Buchsbaum DJ; Forero A; Randall TD
Cancer Immunol Immunother; 2019 Feb; 68(2):175-188. PubMed ID: 30334128
[TBL] [Abstract][Full Text] [Related]
37. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
Wang Y; Xu M; Che M; Von Hofe E; Abbas A; Kallinteris NL; Lu X; Liss ZJ; Forman JD; Hillman GG
Hum Gene Ther; 2005 Feb; 16(2):187-99. PubMed ID: 15761259
[TBL] [Abstract][Full Text] [Related]
38. Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.
Feingold PL; Surman DR; Brown K; Xu Y; McDuffie LA; Shukla V; Reardon ES; Crooks DR; Trepel JB; Lee S; Lee MJ; Gao S; Xi S; McLoughlin KC; Diggs LP; Beer DG; Nancarrow DJ; Neckers LM; Davis JL; Hoang CD; Hernandez JM; Schrump DS; Ripley RT
Mol Cancer Ther; 2018 Sep; 17(9):2013-2023. PubMed ID: 29934340
[TBL] [Abstract][Full Text] [Related]
39. Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.
Hicks KC; Chariou PL; Ozawa Y; Minnar CM; Knudson KM; Meyer TJ; Bian J; Cam M; Schlom J; Gameiro SR
Nat Commun; 2021 Aug; 12(1):5151. PubMed ID: 34446712
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Kurmasheva RT; Bandyopadhyay A; Favours E; Del Pozo V; Ghilu S; Phelps DA; Erickson SW; Peer CJ; Figg WD; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2019 Aug; 66(8):e27820. PubMed ID: 31099166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
